Insulet Corp. (NASDAQ:PODD) Receives Average Rating of “Buy” from Brokerages
Insulet Corp. (NASDAQ:PODD) has earned an average recommendation of “Buy” from the seventeen analysts that are covering the company. Eight investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $41.62.
A number of brokerages have recently issued reports on PODD. B. Riley began coverage on shares of Insulet Corp. in a report on Monday, September 26th. They issued a “neutral” rating and a $46.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $44.00 price target on shares of Insulet Corp. in a report on Wednesday, June 22nd. Zacks Investment Research raised shares of Insulet Corp. from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Tuesday, August 9th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $52.00 price target on shares of Insulet Corp. in a report on Tuesday, August 16th. Finally, Leerink Swann reissued an “outperform” rating and issued a $50.00 price target (up from $40.00) on shares of Insulet Corp. in a report on Thursday, August 4th.
Several hedge funds and other institutional investors have recently modified their holdings of PODD. Walleye Trading LLC boosted its position in shares of Insulet Corp. by 226.3% in the second quarter. Walleye Trading LLC now owns 3,410 shares of the company’s stock valued at $103,000 after buying an additional 6,110 shares in the last quarter. BOKF NA purchased a new position in shares of Insulet Corp. during the second quarter valued at about $111,000. BNP Paribas Arbitrage SA boosted its position in shares of Insulet Corp. by 113.5% in the second quarter. BNP Paribas Arbitrage SA now owns 3,691 shares of the company’s stock valued at $112,000 after buying an additional 1,962 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Insulet Corp. during the second quarter valued at about $261,000. Finally, ProShare Advisors LLC boosted its position in shares of Insulet Corp. by 1.6% in the second quarter. ProShare Advisors LLC now owns 7,055 shares of the company’s stock valued at $213,000 after buying an additional 108 shares in the last quarter.
Insulet Corp. (NASDAQ:PODD) traded up 3.02% during midday trading on Monday, reaching $41.07. 93,507 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $42.31 and a 200-day moving average of $35.32. Insulet Corp. has a 12 month low of $23.94 and a 12 month high of $45.60. The stock’s market cap is $2.35 billion.
Insulet Corp. (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.09. Insulet Corp. had a negative net margin of 17.68% and a negative return on equity of 137.88%. The business had revenue of $87.30 million for the quarter, compared to the consensus estimate of $81.10 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. The company’s revenue was up 44.2% compared to the same quarter last year. On average, equities research analysts predict that Insulet Corp. will post ($0.44) earnings per share for the current year.
Insulet Corp. Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM).
Receive News & Stock Ratings for Insulet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corp. and related stocks with our FREE daily email newsletter.